Nasdaq atai.
(NASDAQ: ATAI) Atai Life Sciences Nv's forecast annual revenue growth rate of 69.84% is forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 35.06%, and it is also forecast to beat the US market's average forecast revenue growth rate of 7.63%.
View the latest ATAI Life Sciences N.V. (ATAI) stock price, news, historical charts, analyst ratings and financial information from WSJ.Atai Life Sciences Nv 's revenue in 2023 is $334,000.On average, 2 Wall Street analysts forecast ATAI's revenue for 2023 to be $124,507,857, with the lowest ATAI revenue forecast at $49,803,143, and the highest ATAI revenue forecast at $199,212,571.- atai has dosed the first subject in their Phase 1 single-ascending dose (SAD) trial of VLS-01 with topline results expected in H1 2023. - VLS-01 is a synthetic form of N,N-dimethyltryptamine ...Clinical-stage psychedelics company atai Life Sciences (NASDAQ:ATAI) reported its financial results and corporate updates for the third quarter ended September 30, 2023.. In numbers: Cash, cash ...
Clinical-stage biopharma company atai Life Sciences (NASDAQ:ATAI) announced the dosing of the first subject in majority-owned subsidiary Perception Neuroscience’s Phase 1 intravenous-to ...Atai Life Sciences (NASDAQ: ATAI) focuses on therapeutics to treat mental health issues, such as anxiety, depression or addiction. This clinical-stage biopharma company went public in June 2021.Atai Life Sciences (NASDAQ:ATAI) closed at $1.06, down from prior weeks’ closings at $1.3, $1.28, $1.39 and $1.29. Incannex Healthcare (NASDAQ:IXHL) closed at $0.99, up from prior week’s close ...
Mar 6, 2023 · NEW YORK and BERLIN, March 06, 2023 (GLOBE NEWSWIRE) -- atai Life Sciences (NASDAQ: ATAI) (“atai”), a clinical-stage biopharmaceutical company aiming to transform the treatment of mental ...
Atai Life Sciences N.V. (NASDAQ:ATAI) Number of Hedge Fund Investors In Q2 2023: 7. Atai Life Sciences N.V. (NASDAQ:ATAI) is a biotechnology company developing treatments for mental health disorders.ATAI Life Sciences News: This is the News-site for the company ATAI Life Sciences on Markets Insider Indices Commodities Currencies StocksBefore this, he was the CFO of atai Life Sciences (Nasdaq: ATAI), where he led a successful IPO, managed the acquisition of multiple mental health therapeutics assets, and raised more than $500 ...On September 27, ATAI Life Sciences (NASDAQ:ATAI), which is developing EMP-01, a 3,4-methylenedioxy-methamphetamine (MDMA) derivative for the treatment of PTSD and other indications, announced ...
The average trading volume of ATAI on November 29, 2023 was 536.92K shares. ATAI) stock’s latest price update. The stock price of ATAI Life Sciences N.V. (NASDAQ: ATAI) has plunged by -3.51 when compared to previous closing price of 1.14, but the company has seen a 2.80% gain in its stock price over the last five trading sessions.
The financial services firm H.C. Wainwright & Co. recently issued a $20 price target on ATAI Life Sciences (ATAI 7.69%) stock. This 12-month price target implies an upside potential of 969% from ...
NEW YORK and BERLIN, Nov. 14, 2023 (GLOBE NEWSWIRE) -- atai Life Sciences (NASDAQ: ATAI) (“atai”), a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health ...Investing.com - ATAI Life Sciences BV (NASDAQ: ATAI) obtuvo en el tercer trimestre del año un BPA de 0.25$, 0.45$ mejor que lo esperado, pues se preveía un BPA de -0.20$.Los ingresos del trimestre se situaron en 87K$, frente a una previsión de 0$. Las acciones de ATAI Life Sciences BV cerraron en 1.15$, lo que representa una cayó un …NEW YORK and BERLIN, Jan. 06, 2023 (GLOBE NEWSWIRE) -- atai Life Sciences (NASDAQ: ATAI) (“atai” or “the Company”), a clinical-stage biopharmaceutical company focused on mental health ...NEW YORK and BERLIN, Oct. 06, 2023 (GLOBE NEWSWIRE) -- atai Life Sciences (NASDAQ: ATAI) (“atai”), a clinical-stage biopharmaceutical company aiming to …atai Life Sciences Announces Results from the Kures Therapeutics Phase 1 Trial of KUR-101. - This two-part phase 1 trial in healthy volunteers was designed to assess the safety, pharmacokinetics ...
Find the latest Earnings Report Date for ATAI Life Sciences N.V. Common Shares (ATAI) at Nasdaq.com.Quotes delayed 15 minutes for NASDAQ, NYSE and AMEX. Copyright © 2007-2023 FINVIZ.com. All Rights Reserved. Quantcast. × ...Net loss attributable to ATAI Life Sciences N.V. stockholders $ (45,011) $ (88,877) $ (152,385) $ (167,808) Net loss per share attributable to ATAI Life Sciences N.V. stockholders — basic and ...ATAI Life Sciences N.V. (NASDAQ:ATAI)’s traded shares stood at 0.58 million during the last session, with the company’s beta value hitting 0.86. At the close of trading, the stock’s price was $1.32, to imply an increase of 6.45% or $0.08 in intraday trading. The ATAI share’s 52-week high ...NASDAQ Health Care/Life Sciences Compare to Open 1.08 Prior Close 1.04 (11/30/23) 1 Day ATAI 7.21% DJIA 0.30% Russell 2K 1.41% Health Care/Life Sciences 0.38% Overview Per-Share Earnings,...Jul 16, 2021 ... ATAI Life Sciences N.V.(Nasdaq:ATAI): ATAI Life Sciences N.V (ATAI), Compass Pathways Plc (CMPS), and Mind Medicine Holdings (MNMD) are 3 ...
With its shares down by 60% in the last 12 months and a recent layoff affecting 30% of its workforce, it's fair to say that Atai Life Sciences (ATAI-1.75%) is having a rough go of things lately ...NEW YORK and BERLIN, Jan. 09, 2023 (GLOBE NEWSWIRE) -- Today, atai Life Sciences N.V. (Nasdaq: ATAI) (“atai” or “the Company”), a clinical-stage biopharmaceutical company aiming to ...
The average one-year price target for ATAI Life Sciences N.V. (NASDAQ:ATAI) has been revised to 12.57 / share. This is an increase of 5.04% from the prior estimate of 11.97 dated August 31, 2023.Get ATAI Life Sciences BV (ATAI) share price today and stock analysis, price valuation, performance, fundamentals, market cap, shareholding, ...Nov 17, 2023 ... atai Life Sciences N.V. (ATAI) appears an attractive pick, as it has been recently upgraded to a Zacks Rank #2 (Buy).Dec 13, 2021 · NEW YORK, Dec. 13, 2021 (GLOBE NEWSWIRE) -- atai Life Sciences N.V. (Nasdaq: ATAI) (“atai”), a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health ... With its shares down by 60% in the last 12 months and a recent layoff affecting 30% of its workforce, it's fair to say that Atai Life Sciences ( ATAI 1.87%) is having a rough go of things lately ...ATAI Life Sciences N.V. Common Shares ... Nasdaq.com will report pre-market and after hours trades. Pre-Market trade data will be posted from 4:15 a.m. ET to 7:30 a.m. ET of the following day.
(NASDAQ: KTTA), COMPASS Pathways plc (NASDAQ: CMPS), Field Trip Health Ltd. (NASDAQ: FTRP) (TSX: FTRP), Cybin Inc. (NYSE: CYBN), atai Life Sciences (NASDAQ: ATAI). Grand View Research continued with: “Presence of strong pipeline products by major pharmaceutical companies … are expected to accelerate market …
Jan 18, 2022 ... In December, it was announced that atai would be added to the Nasdaq's prestigious biotechnology index. ... Atai Life Sciences Has Been Selected ...
Last week, I reported for Psychedelic Spotlight that famed investor Cathie Woods was dipping her toes into the world of psychedelic stocks. On February 8th, ARK’s Genomic Revolution ETF (BATS: ARKG) made an initial investment into the best financed psychedelic medicines company, atai Life Sciences (Nasdaq: ATAI).. I said at the time …atai Life Sciences (NASDAQ: ATAI) (“atai”), a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health disorders, reported third quarter 2023 financial results and provided corporate updates. “As the burden of unmet medical needs in mental health care continues to grow, our team remains …(Part four of a four-part series) See previous stories in this series: Insider's Peek At Mammoth Of Psychedelics VCs, Palo S...NEW YORK and BERLIN, Nov. 01, 2022 (GLOBE NEWSWIRE) -- atai Life Sciences N.V. (Nasdaq: ATAI) (“atai”), a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health disorders, will participate in the following investor events & healthcare conferences: Financial Times Pharma and Biotech Summit in LondonThe Company’s $209M cash position and committed term loan funding is expected to fund operations into 1H 2026. NEW YORK and BERLIN, Nov. 14, 2023 (GLOBE NEWSWIRE) -- atai Life Sciences (NASDAQ ...NEW YORK and BERLIN, Oct. 06, 2023 (GLOBE NEWSWIRE) -- atai Life Sciences (NASDAQ: ATAI) (“atai”), a clinical-stage biopharmaceutical company aiming to …Based on analysts offering 12 month price targets for ATAI in the last 3 months. The average price target is $ 0.00 with a high estimate of $ 0.00 and a low estimate of $ 0.00 . 3. Psychedelics Stocks Rise In First Post-Tax Loss Selling Week. The psychedelic sector rose moderately in the first week of 2023 past week, as reflected by the Horizon Psychedelic Stock Index (PSYK) ETF ↑4.70%.Despite a negative readout for atai Life Sciences compound PCN-101, the market ended higher and sharply outperformed …NEW YORK, Sept. 21, 2021 (GLOBE NEWSWIRE) -- DemeRx IB, Inc. ("DemeRx"), an atai Life Sciences (Nasdaq: ATAI) ("atai") platform company focused on developing ibogaine for the treatment of opioid ...With a Buy rating, Baader Helvea initiated coverage on ATAI Life Sciences NV (NASDAQ:ATAI). The price target seems to have been set at $21.00 for ATAI Life Sciences. The stock has a 52-week-high ...Atai Life Sciences N.V. (NASDAQ:ATAI) Number of Hedge Fund Investors In Q2 2023: 7 Atai Life Sciences N.V. (NASDAQ:ATAI) is a biotechnology company developing treatments for mental health disorders.
Oct 31, 2023 · Atai Life Sciences N.V. (NASDAQ:ATAI) Number of Hedge Fund Investors In Q2 2023: 7 Atai Life Sciences N.V. (NASDAQ:ATAI) is a biotechnology company developing treatments for mental health disorders. He was an early stakeholder in Atai Life Sciences (NASDAQ:ATAI), a startup with 10 psychedelic programs in the works and that count Peter Thiel as one of its primary investors.Real time Atai Life Sciences (ATAI) stock price quote, stock graph, news & analysis.Instagram:https://instagram. best personal advisor servicescubrenliberty silver dollar value 1921bno etf Nov 14, 2023 · The Company’s $209M cash position and committed term loan funding is expected to fund operations into 1H 2026. NEW YORK and BERLIN, Nov. 14, 2023 (GLOBE NEWSWIRE) -- atai Life Sciences (NASDAQ ... ultra wealthybest insurance for orthodontics Find the latest Insider Activity data for ATAI Life Sciences N.V. Common Shares (ATAI) at Nasdaq.com. ... Nasdaq Insider Activity page provides trading information of corporate insiders (officers ... vohix Dec 1, 2023 · ATAI Life Sciences NV is a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health disorders. Its product candidates include COMP360/Psilocybin therapy, PCN-101 ... According to the issued ratings of 4 analysts in the last year, the consensus rating for Atai Life Sciences stock is Buy based on the current 4 buy ratings for ATAI. The average twelve-month price prediction for Atai Life Sciences is $12.80 with a high price target of $20.00 and a low price target of $9.00. Learn more on ATAI's analyst rating ...NEW YORK and BERLIN, Nov. 14, 2023 (GLOBE NEWSWIRE) -- atai Life Sciences (NASDAQ: ATAI) (“atai”), a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health ...